{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:57:19Z","timestamp":1790128639173,"version":"4.0.1"},"reference-count":26,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Chronic spontaneous urticaria (CSU) presents with unpredictable, often debilitating symptoms, yet detailed clinical characterization, particularly in pediatric populations, remains limited. Improved understanding of clinical profiles and comorbidities may guide\n management strategies.\n                    <jats:bold>Objective:<\/jats:bold>\n                    The objective was to characterize clinical presentation, comorbid type 2 inflammatory diseases, and treatment responses in a large cohort of pediatric and adult patients with CSU across multiple allergy practices.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A retrospective observational cohort study was conducted across four U.S. allergy clinics, including two pediatric- and two adult-focused practices. Medical records of 400 patients with CSU (189 pediatric patients, 211 adults) with \u2265 6 months of follow-up between 2013 and 2023 were\n reviewed for demographic data, comorbidities, clinical presentation, clinician-documented disease severity, and treatment outcomes.\n                    <jats:bold>Results:<\/jats:bold>\n                    Disease severity spanned mild (24%), moderate (28%), and severe (48%) disease; adults more often presented with severe disease (65%\n versus 32% in pediatric patients). Atopic comorbidities were common, including allergic rhinitis (72%), asthma (38%), and atopic dermatitis (17%), with 43% of patients having two or more type 2 inflammatory comorbidities. H\n                    <jats:sub>1<\/jats:sub>\n                    -antihistamines were the most frequently used therapies,\n with cetirizine being most common. Omalizumab showed effectiveness in most patients, although \u223c31% experienced partial or no response. Systemic corticosteroids and cyclosporine were used infrequently. Sparse documentation of physical findings and laboratory analysis limited further objective\n analysis.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This U.S. multicenter study highlights the substantial burden of atopic disease and refractory CSU in both pediatric and adult populations. These findings emphasize the need for prospective studies with standardized clinical documentation to better\n understand CSU phenotypes and optimize individualized treatment strategies.\n                  <\/jats:p>","DOI":"10.2500\/aap.2026.47.260012","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:42:02Z","timestamp":1777437722000},"page":"190-195","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics, type 2 comorbidities, and treatment responses in pediatric and adult chronic spontaneous urticaria: A multicenter retrospective cohort study"],"prefix":"10.2500","volume":"47","author":[{"given":"Kathryn","family":"Smiley","sequence":"first","affiliation":[{"name":"From the Division of Allergy and Immunology, Allergy and Asthma Medical Group and Research Center, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Galli","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology, Allergy and Asthma Medical Group and Research Center, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Grippen Goddard","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Allergy Partners of Albuquerque, Albuquerque, New Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Allergy, Asthma and Immunology, Children's Hospital of the King\u2019s Daughters, Norfolk, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Smigiel","sequence":"additional","affiliation":[{"name":"Allergy and Asthma Specialist Doctors, Inc., Pasadena, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoushka","family":"Tambay","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology, Allergy and Asthma Medical Group and Research Center, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Barseghyan","sequence":"additional","affiliation":[{"name":"Allergy and Asthma Specialist Doctors, Inc., Pasadena, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashly","family":"Probst","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Allergy Partners of Albuquerque, Albuquerque, New Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Allergy, Asthma and Immunology, Children's Hospital of the King\u2019s Daughters, Norfolk, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Navasero","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology, Allergy and Asthma Medical Group and Research Center, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Wetklow","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology, Allergy and Asthma Medical Group and Research Center, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of California San Diego, San Diego, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Geng","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology, Allergy and Asthma Medical Group and Research Center, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The International EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.3390\/jcm12237482","article-title":"Epidemiological and clinical characteristics of adult and pediatric patients with chronic spontaneous urticaria","volume":"12","author":"Barzilai","year":"2023","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE CSU","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/all.13182","article-title":"Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review","volume":"72","author":"Kolkhir","year":"2017","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"crossref","first-page":"100097","DOI":"10.1016\/j.waojou.2019.100097","article-title":"Risk of comorbidities in patients diagnosed with chronic urticaria: a nationwide registry-study","volume":"13","author":"Ghazanfar","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B6","doi-asserted-by":"crossref","first-page":"100843","DOI":"10.1016\/j.waojou.2023.100843","article-title":"Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria","volume":"16","author":"Soong","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B7","first-page":"S10","article-title":"The urticaria voices study: antihistamine treatment patterns and patient reported control in chronic spontaneous urticaria","volume":"131","author":"Bernstein","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13223-020-00459-5","article-title":"Natural history, prognostic factors and patient perceived response to treatment in chronic spontaneous urticaria","volume":"16","author":"Stepaniuk","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.anai.2024.12.008","article-title":"Clinical burden, treatment, and disease control in patients with chronic spontaneous urticaria: real-world evidence","volume":"134","author":"Riedl","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamadermatol.2017.3182","article-title":"Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic urticaria","volume":"153","author":"Netchiporouk","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaip.2017.10.001","article-title":"The urticaria activity score \u2013 validity, reliability, and responsiveness","volume":"6","author":"Hawro","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.jaip.2022.02.033","article-title":"Validation of UAS7 among children with chronic spontaneous urticaria","volume":"10","author":"Gabrielli","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"crossref","first-page":"e13925","DOI":"10.1111\/pai.13925","article-title":"Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: clinical features, associated conditions and indicators of treatment response","volume":"34","author":"\u00d6z\u00e7eker","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jdermsci.2008.04.002","article-title":"Sex hormones and urticaria","volume":"52","author":"Kasperska-Zajac","year":"2008","journal-title":"J Dermatol Sci"},{"key":"B15","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1111\/all.14950","article-title":"Effects of pregnancy on chronic urticaria: results of the PREG-CU UCARE study.","volume":"76","author":"Kocat\u00fcrk","year":"2021","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1016\/j.jaip.2021.09.002","article-title":"Atopy: a collection of comorbid conditions","volume":"9","author":"Diaz-Cabrera","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/bjd.15347","article-title":"Chronic urticaria and atopic disorders: a cross-sectional study of 11 271 patients","volume":"177","author":"Shalom","year":"2017","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jaad.2019.02.034","article-title":"Characterization of chronic urticaria and associated conditions in a large population of adolescents","volume":"81","author":"Rosman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jaci.2020.03.005","article-title":"The role of eosinophils in chronic spontaneous urticaria","volume":"145","author":"Altrichter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/ITT.S261416","article-title":"Anti-IgE for the treatment of chronic urticaria","volume":"10","author":"Wedi","year":"2021","journal-title":"Immunotargets Ther"},{"key":"B22","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jaip.2022.09.038","article-title":"Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring","volume":"10","author":"Kocaturk","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"crossref","first-page":"AB366","DOI":"10.1016\/j.jaci.2023.11.873","article-title":"Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: top line results from a phase 2 trial","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B26","article-title":"Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria. GlobeNewswire.","year":"2025"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000003\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:45:59Z","timestamp":1782535559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,1]]}},"alternative-id":["1088-5412(20260501)47:3L.190;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260012","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}